Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:G16B* AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/237292METHODS OF ASSESSING RISK OF DEVELOPING A SEVERE RESPONSE TO CORONAVIRUS INFECTION
WO 02.12.2021
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
Appl.No PCT/AU2021/050507 Applicant GENETIC TECHNOLOGIES LIMITED Inventor DITE, Gillian Sue
The present disclosure relates to methods and systems for assessing the risk of a human subject developing a severe response to a Coronavirus infection, such as a severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus infection.
2.20210102197DESIGNING SENSITIVE, SPECIFIC, AND OPTIMALLY ACTIVE BINDING MOLECULES FOR DIAGNOSTICS AND THERAPEUTICS
US 08.04.2021
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
Appl.No 17065504 Applicant THE BROAD INSTITUTE, INC. Inventor Pardis SABETI

The invention provides for methods for designing sensitive, specific, and optimally active binding molecules. Systems, methods and compositions utilizing the designed molecules in diagnostics and therapeutics are also provided.

3.WO/2022/140706IMMUNE-REGULATORY LI-KEY PEPTIDE VACCINES FOR PROPHYLAXIS AND LONG-TERM PROTECTION AGAINST SARS-COV-2 INFECTION AND COVID-19 DISEASE
WO 30.06.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/065178 Applicant PURCELL, Richard, D. Inventor PURCELL, Richard, D.
The disclosure details methods for producing peptide-based vaccines for immunizing mammalian subjects against the SARS Coronavirus SARS-CoV-2, and additionally describes peptide vaccines and methods for immunizing mammalian subjects, including humans, to elicit a protective immune response against SARS-CoV-2 and to prevent or reduce the severity of COVID- 19 disease. Additionally, the disclosure provides methods and compositions for making and using li-Key peptide fusions with SARS-CoV-2 antigenic peptides to make immunogenic Ii-Key-SARS-CoV-2 peptide hybrid constructs exhibiting increased MHC presentation-based immune cell activation useful for vaccines against SARS-CoV-2.
4.WO/2021/216615HIGHLY-NETWORKED CORONAVIRUS IMMUNOGEN COMPOSITION
WO 28.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/028245 Applicant THE GENERAL HOSPITAL CORPORATION Inventor GAIHA, Gaurav
A method of preventing or treating COVID infection in a subject includes selecting two or more COVED CTL epitopes from a Coronavirus proteome that have a network score that meets a threshold value. An effective amount of a T cell immunogen composition and a pharmaceutically acceptable carrier is administered to the subject. The T cell immunogen composition includes the two or more selected Coronavirus CTL epitopes.
5.WO/2022/081920SYSTEMS FOR AND METHODS OF TREATMENT SELECTION
WO 21.04.2022
Int.Class G01N 33/567
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
566using specific carrier or receptor proteins as ligand binding reagent
567utilising isolate of tissue or organ as binding agent
Appl.No PCT/US2021/055096 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor KROGAN, Nevan
The disclosure relates to a system comprising software that predicts responsiveness of subjects to certain disease modifying drugs. Embodiments of the disclosure include methods comprising calculating a differential interaction score (DIS), correlating the DIS with the likelihood that a dysfunctional protein-protein interaction is the causal agent of a disease or disorder, and identifying a subject responsive to a treatment based upon the causal agent.
6.3892298EPITOPES HAVING SEQUENCE HOMOLOGY TO CORONAVIRUS SPIKE PROTEIN SUBUNIT AND USES THEREOF
EP 13.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 20169101 Applicant PREVIPHARMA CONSULTING GMBH Inventor KIESSIG STEPHAN T
The present invention relates to polypeptides comprising epitopes having a sequence homology to a sequence section of subunit S1 and/or subunit S2 of coronavirus spike protein from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the present invention refers to a vaccine comprising such polypeptide. The invention further relates to an antibody binding to subunit S1 and/or subunit S2 and to methods for isolating and detecting such antibody and to uses of the polypeptides and antibodies.
7.WO/2021/191829ASSAYS FOR DETECTING PATHOGENS
WO 30.09.2021
Int.Class C12Q 1/6869
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6869Methods for sequencing
Appl.No PCT/IB2021/052463 Applicant ANGSTROM BIO, INC. Inventor SANTOS, Carlos F.
Provided herein are compositions and methods for identifying target nucleic acids that are determinants of pathogenic infections. The multiplexed methods provided herein simultaneously detect target proteins such as IgG and IgM immunoglobulins that are indicative of one or more pathogenic infections, from several distinct biological samples. Also provided herein are methods for detecting sequence variants in a nucleic acid sample.
8.20210388031Designer Peptide Opsonins
US 16.12.2021
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No 17348994 Applicant New Jersey Institute of Technology Inventor Dr. Vivek A. Kumar

Disclosed is a new strategy, composition, and method for a self-assembling peptides (SAP) that will self-assemble atop COVID-19 for immune destruction and act as a functional COVID-19 opsonin. The designed self-assembling peptides bind and assemble atop SARS-CoV-2—providing a new mechanism of infection abrogation. One benefit is avoidance of side effects that other formulations or repurposed drugs contain. Other feature of this technology include: (a) (SAP) are composed of L-amino acids that are highly biocompatible sub-Q, IM and IV (no adverse reaction for 10% blood volume replacement with 1 w % peptide in mice or rats); (b) Highly targeted approach that binds to viral particles preventing side effects; (c) SAP are intrinsically biodegradable and endocytosed; (d) SAP bound COVID-19 may promote engulfment, clearance, and antigen presentation (for immunity development); and (e) targeting the spike protein with SAP may allow treatment of other coronaviruses.

9.3112051PRO-ADRENOMEDULLIN OR FRAGMENT THEREOF IN PATIENTS INFECTED WITH CORONA VIRUS AND TREATMENTS WITH BINDER AGAINST ADRENOMEDULLIN
CA 16.09.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No 3112051 Applicant SPHINGOTEC GMBH Inventor

Subject matter of the present invention is a method for (a) diagnosing or
predicting the risk of
life-threatening deterioration or an adverse event or (b) prognosing the
severity or (c) predicting
or monitoring the success of a therapy or intervention in a patient infected
with a Corona virus,
the method comprising:
= determining the level of pro-Adrenomedullin (SEQ ID No. 31) or fragment
thereof in a sample of bodily fluid of said patient,
= comparing said level of pro-Adrenomedullin or fragment thereof to a pre-
determined threshold or a previous level of pro-Adrenomedullin or fragment
thereof, and
= correlating said level of pro-Adrenomedullin or fragment thereof with the
risk
of life-threatening deterioration or an adverse event, or
= correlating said level of pro-Adrenomedullin or fragment thereof with the

severity, or
= correlating said level of pro-Adrenomedullin or fragment thereof with the

success of a therapy or intervention,
wherein said pro-Adrenomedullin or fragment thereof is selected from the group
consisting of
PAMP (SEQ ID No. 32), MR-proADM (SEQ ID No. 33), ADM-NH2 (SEQ ID No. 20), ADM-
Gly (SEQ ID No. 21) and CT-proADM (SEQ ID No. 34).
Subject matter of the present invention is an Anti-adrenomedullin (ADM)
antibody or anti-
ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy or
intervention in a
patient in a patient infected with a Corona virus.

10.WO/2021/222869METHODS TO DETECT A VIRUS IN A BIOLOGICAL SAMPLE
WO 04.11.2021
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
Appl.No PCT/US2021/030354 Applicant THE TRUSTEES OF INDIANA UNIVERSITY Inventor GILL, Hunter Matthias
Disclosed are methods to characterize at least one virus in at least one human patient by (a) extracting a viral polynucleotide from a biological sample from the at least one human patient, (b) sequencing the viral polynucleotide to generate viral polynucleotide sequence data; and, (c) characterizing the viral polynucleotide sequence data. Further aspects of the invention may include a system which enables user to quickly and accurately search and/or add to data bases that facilitate the identification and/or treatment of diseases caused by viruses.